People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...

for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

SPRAVATO® is unique and works by targeting glutamate, which is the most abundant excitatory neurotransmitter in the brain.6 The mechanism by which esketamine exerts its antidepressant effect is ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...